Table 2.
Subject ID | Gleason | Site of metastasis | Pre-abiraterone PSA | Abiraterone dose % |
---|---|---|---|---|
1001 | 8(4 + 4) | Bone, soft tissue | 6.06 | 62% |
1002 | 8(4 + 4) | Bone | 58.57 | 55% |
1003 | 9 (5 + 4) | Bone, lymph node | 68 | 42% |
1005 | 7(4 + 3) | Lymph node | 95.86 | 87% |
1006 | 8(4 + 4) | Bone | 15.25 | 23% |
1007 | 6(3 + 3) | Bone | 109.4 | 21% |
1009 | 6(3 + 3) | Bone | 13.55 | 53% |
1010 | 7(3 + 4) | Bone | 17.33 | 45% |
1011 | 9(4 + 5) | Lymph node | 2.42 | 53% |
1012 | 8(4 + 4) | Bone | 4.17 | 21% |
1014 | 7(4 + 3) | Bone | 11.83 | 52% |
Average cumulative abiraterone | 47% |
The cumulative abiraterone dose as a percentage of SOC dose is shown for each patient in the trial